Related Experiment Video
Updated: Jun 16, 2026
08:26
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
1.9K
SENECA study: staging endometrial cancer based on molecular classification
Enrique Chacon1, Felix Boria2, R Rajagopalan Lyer3
1Department of Gynecologic Oncology, Universidad de Navarra, Pamplona, Navarra, Spain echaconc@unav.es.
Summary
Sentinel lymph node (SLN) involvement in early-stage endometrial cancer varies significantly by molecular subtype. p53 abnormal and mismatch repair deficient groups show higher SLN metastasis rates, impacting staging and treatment decisions.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Surgical Oncology
Background:
- Accurate staging is critical for effective endometrial cancer management.
- Understanding sentinel lymph node (SLN) involvement across molecular subtypes is essential for refining staging and treatment strategies.
- The European Society of Gynaecological Oncology (ESGO) classification provides a framework for risk stratification.
Purpose of the Study:
- To evaluate sentinel lymph node (SLN) involvement in early-stage (International Federation of Gynecology and Obstetrics 2009 I-II) endometrial cancer.
- To assess the impact of molecular subtypes and ESGO risk classification on SLN metastasis rates.
- To inform treatment decisions by elucidating patterns of SLN involvement.
Main Methods:
- Retrospective analysis of the SENECA study data from 2139 patients with stage I-II endometrial cancer across 66 centers.
- Patients underwent surgery with SLN assessment between January 2021 and December 2022, following ESGO guidelines.
- Molecular analysis (p53, NSMP, MMRd, POLE) was performed on pre-operative biopsies or hysterectomy specimens; SLN assessment utilized ultrastaging or one-step nucleic acid amplification.
Main Results:
- Overall SLN involvement was 9.6% (205/2139 patients), with 67.8% having low-volume metastases.
- Significant differences in SLN involvement were observed among molecular subtypes: p53 abnormal (12.50%) and MMRd (12.40%) had higher rates than NSMP (7.80%) and POLE-mut (6.30%) (p=0.004).
- SLN involvement rates increased with ESGO risk groups, ranging from 2.84% (low-risk) to 22.51% (high-risk).
Conclusions:
- Molecular subtypes significantly influence sentinel lymph node (SLN) involvement in early-stage endometrial cancer.
- p53 abnormal and MMRd subtypes exhibit a higher propensity for SLN metastasis.
- These findings highlight the importance of integrating molecular profiling into staging and treatment planning for endometrial cancer.
More Related Videos
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
11.3K
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.1K
Related Concept Videos
02:57Meiosis vs. Mitosis
Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...